CD117 and Ki-67 expression in gastrointestinal stromal tumors of various morphological variants and localization.

Authors

  • I. S. Shpon’ka ДЗ «Дніпропетровська медична академія МОЗ України», Ukraine
  • V. R. Yakovenko ДЗ «Дніпропетровська медична академія МОЗ України», Ukraine

DOI:

https://doi.org/10.26641/1997-9665.2014.1.104-108

Keywords:

gastrointestinal stromal tumors, immunohistochemistry, proliferative activity, Ki-67, CD117

Abstract

Background. Gastrointestinal stromal tumors are considered as the most frequently occurring tumors of mesenchymal origin in the gastrointestinal tract. Despite active research work in this field many problems in the diagnosis and prognosis of the disease are still unresolved. Objective. To evaluate the interrelations between clinical and morphological characteristics of gastrointestinal stromal tumors, including expression of proliferative activity marker Ki -67, and specific histogenetic marker CD117. Methods. 47 samples were divided into 2 groups: СD117-positive and СD117–negative; each group was divided into subgroups using the following criteria: age, histological structure, localization, expression of Ki-67. Statistical processing of the data included nonparametric tests. Results. Gastrointestinal stromal tumors are more frequent in patients of age group over 60 years, with localization in the stomach and fusiform type of the structure. Comparative analysis of the subgroups with different expression of СD117 did not reveal any significant differences. Conclusion. Data analysis did not reveal any interrelation between the expression of CD117 and clinical or morphological parameters (p>0,05). However, the high rate of Ki-67 expression in stomach neoplasms is less common than in tumors of other localization. Taken together these data evidence the existence of the interrelations between immunohistochemical characteristics and clinical data.

References

  1. Seryakov AP. [Gastrointestinal stromal tumors]. Russian Journal of Gastroenterology, Hepatology and Coloproctology. 2010;(4):49-57. Russian.
  2. Steigen SE, Eide TJ. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS. 2006 Mar;114(3):192-200. Cited in: PubMed; PMID: 16643186.
  3. Miettinen M1, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83. Cited in: PubMed; PMID: 17193820.
  4. Vij M, Agrawal V, Kumar A, Pandey R. Gastrointestinal stromal tumors: A clinicopathological and immunohistochemical study of 121 cases. Indian J Gastroenterol. 2010 Nov;29(6):231-6. doi: 10.1007/s12664-010-0079-z. Cited in: PubMed; PMID: 21221881.
  5. De Vogelaere K, Aerts M, Haentjens P, De Grève J, Delvaux G. Gastrointestinal stromal tumor of the stomach: progresses in diagnosis and treatment. Acta Gastroenterol Belg. 2013 Dec;76(4):403-6. Cited in: PubMed; PMID: 24592543.
  6. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002 May;33(5):459-65. Cited in: PubMed; PMID: 12094370
  7. Hamilton SR, Aaltonen LA, editors: World Health Organisation classificatoin of tumors: Pathology and genetics of tumors of the digestive system. Lyon: IARC Press; 2000. 314p.
  8. Odze RD, Goldblum JR, Crawford JM. Surgical pathology of GI tract, liver, biliary tract, and pancreas. 1st ed. Pennsylvania: Elsevier; 2004. 1067p.
  9. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012 Mar 15;18(6):1769-76. doi: 10.1158/1078-0432.CCR-11-2230. Cited in: PubMed; PMID: 22282465.
  10. Killian JK, Kim SY, Miettinen M, Smith C, Merino M, Tsokos M, Quezado M, Smith WI Jr, Jahromi MS, Xekouki P, Szarek E, Walker RL, Lasota J, Raffeld M, Klotzle B, Wang Z, Jones L, Zhu Y, Wang Y, Waterfall JJ, O'Sullivan MJ, Bibikova M, Pacak K, Stratakis C, Janeway KA, Schiffman JD, Fan JB, Helman L, Meltzer PS. Suc-cinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 2013 Jun;3(6):648-57. doi: 10.1158/2159-8290.CD-13-0092. Cited in: PubMed; PMID: 23550148.
  11. Wang C, Jin MS, Zou YB, Gao JN, Li XB, Peng F, Wang HY, Wu ZD, Wang YP, Duan XM. Diagnostic significance of DOG-1 and PKC-θ ex-pression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours. Scand J Gastroenterol. 2013 Sep;48(9):1055-65. doi: 10.3109/00365521.2013.816770. Cited in: PubMed; PMID: 23862765.

Downloads

How to Cite

Shpon’ka, I. S., & Yakovenko, V. R. (2014). CD117 and Ki-67 expression in gastrointestinal stromal tumors of various morphological variants and localization. Морфологія / Morphologia / Morfologìâ, 8(1), 104–108. https://doi.org/10.26641/1997-9665.2014.1.104-108

Issue

Vol. 8 No. 1 (2014)

Section

Статті

License

Copyright (c) 2018 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.